Ultragenyx Pharmaceutical Inc. appointed Camille L. Bedrosian, M.D. as Executive Vice President and Chief Medical Officer. In this role, Dr. Bedrosian will provide strategic leadership to the clinical development and translational research programs, and will oversee Medical Affairs, Global Clinical Development groups, Clinical Operations and Drug Safety/Pharmacovigilance. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team. Most recently, Dr. Bedrosian was Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals Inc.